Immune checkpoint inhibition in bone metastases: lesion response heterogeneity, the osteoimmune niche, and microenvironment-directed therapy
Min Dong, Guili Zheng, Fangyuan Yu, Jiaqi Yin, Chen Zhong · 2026
Read Immune checkpoint inhibition in bone metastases: lesion response heterogeneity, the osteoimmune niche, and microenvironment-directed therapy by Min Dong, Guili Zheng, Fangyuan Yu, Jiaqi Yin, Chen Zhong (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13627993.txt.
Description
Cancer that spreads to bone often responds poorly to immune checkpoint drugs. Min Dong, Guili Zheng, Fangyuan Yu, Jiaqi Yin, and Chen Zhong review why. Bone lesions can follow a different course from soft-tissue lesions in the same patient. Standard measuring rules handle bone badly, and healing bone can mimic growth on scans. Inside the bone, a special immune niche forms. Abnormal remodeling, suppressive myeloid cells, and weak T-cell entry all blunt the attack.
Bone-targeted drugs and radiation might reopen that niche. Evidence that they boost checkpoint therapy is not yet solid. The authors separate true drug resistance from the worse starting outlook of these patients.
Catalog record
| CREATOR | Min Dong, Guili Zheng, Fangyuan Yu, Jiaqi Yin, Chen Zhong |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 72 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |